Navigation Links
Experimental Drug Promising Against Tough-to-Treat Asthma

By Amanda Gardner
HealthDay Reporter

WEDNESDAY, Aug. 3 (HealthDay News) -- A new experimental drug for adults with asthma seems to improve lung function in patients who haven't been helped with standard steroids.

The drug, lebrikizumab, targets a specific receptor involved in asthma, and appears to be the first drug to be successful in this particular approach, said Dr. Steve Georas, a professor of medicine in the pulmonary and critical care division at the University of Rochester Medical Center.

It is also perhaps the first drug to have this specific effect in asthmatics, and may lead to more gains in individualized treatments for patients.

"Personalized medicine hasn't made huge strides in asthma," said Georas. "We're all hopeful we're on the verge of a new era in that regard. This appears to be a first tentative step in that direction."

Georas was not involved with the new research, which appears in the Aug. 3 issue of the New England Journal of Medicine and was funded by Genentech, which makes lebrikizumab.

Lebrikizumab is a monoclonal antibody that binds to interleukin-13 (IL-13), a signaling molecule involved in the inflammatory responses associated with asthma.

Although glucocorticoids also inhibit IL-13, the molecule manages to exert its influence in other ways which, so far, have eluded current medications. But, lebrikizumab works in a different way than traditional steroids.

The authors randomized 219 adults who had not responded to standard treatments to receive either lebrikizumab or a placebo.

After three months, the overall group of patients taking lebrikizumab saw a 5.5 percent improvement in their FEV1 (forced expiratory volume in one second), which measures how much a person expels when exhaling, compared to the placebo group.

Patients who had high IL-13 levels (as measured by the protein periostin, which is produced by IL-13) saw an FEV1 improvement of 8.2 percent with lebrikizumab versus the placebo.

By contrast, in the low-periostin group, the improvement was only 1.6 percent higher.

While overall side effects were roughly the same in both groups, there were more musculoskeletal effects in the lebrikizumab group (13.2 percent in the treatment arm versus 5.4 percent in the placebo group).

In addition to the fact that the drug is not yet approved, lebrikizumab may have other issues.

For one thing, it's not clear if clinics can easily measure levels of periostin, said Georas. That would be key in determining who would and who wouldn't benefit from the drug.

Also, lebrikizumab is given as an injection once a month, something that many patients are reluctant to do. Even inhaled medications -- especially glucocorticoids which can take days or weeks to help -- aren't overly popular with patients, said Dr. Susanna Von Essen, a professor of pulmonary and critical care medicine at the University of Nebraska Medical Center in Omaha.

"People like pills better than inhaled medications and usually injections are down the list but, if it causes improvement, you will find some patients who will accept it," she said.

Also, this breaks new ground in blocking IL-13 so "maybe this will be the beginning of a series of medications that attack the IL-13 molecule and maybe they'll come up with something inhaled or something you can swallow," she said.

More information

The American Lung Association has more on asthma.

SOURCES: Steve Georas, M.D., professor, medicine, pulmonary and critical care division, University of Rochester Medical Center, Rochester, N.Y.; Susanna Von Essen, M.D., professor, pulmonary and critical care medicine, University of Nebraska Medical Center, Omaha; Aug. 3, 2011, New England Journal of Medicine

Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. University Hospitals Case Medical Center to begin clinical trial on experimental anti-TB drug
2. Experimental Drug Might Help Fight Alzheimers After All
3. Experimental Drug Bests Chemo in Non-Small Cell Lung Cancer Study
4. Experimental Vaccine Seems to Cure Prostate Cancer in Mice
5. ASCO: Experimental vaccine made from frozen immune cells shows promise for prostate cancer patients
6. Ex-Dallas Maverick survives rare form of leukemia thanks to experimental drug treatment
7. Experimental treatment offers relief from painful prostate condition
8. Christos Mantzoros honored by Federation of the American Societies for Experimental Biology
9. Experimental Test May Warn of Premature Births
10. Experts at Experimental Biology examine dietary cholesterol, egg intake and heart disease risk
11. Experimental Weight-Loss Drug Seems to Work: Study
Post Your Comments:
Related Image:
Experimental Drug Promising Against Tough-to-Treat Asthma
(Date:11/27/2015)... ... November 27, 2015 , ... According to an ... the University of Toronto and the University of British Columbia suggested that laws requiring ... injuries. The article explains that part of the reason for the controversial conclusion is ...
(Date:11/27/2015)... (PRWEB) , ... November 27, 2015 , ... ... a safe and convenient way to dispense prescription medications at home, so he ... effective way to monitor and dispense prescription medications. In doing so, it could ...
(Date:11/27/2015)... ... 27, 2015 , ... ProSidebar: Fashion is a set of 30 ... ProSidebar: Fasion, video editors can easily add an informative sidebar to any FCPX production. ... Utilize presets featuring self-animating drop zones, lines, bars, and text with the ease of ...
(Date:11/27/2015)... (PRWEB) , ... November 27, 2015 , ... A simply ... Jones, is an interesting show that delves into an array of issues that are ... that could benefit from open dialogue, this show is changing the subjects consumers focus ...
(Date:11/27/2015)... ... November 27, 2015 , ... ... successful and prominent nonprofit healthcare organizations in the country. They have overseen financial ... organizations, and helped advance the healthcare industry as a whole through their advocacy ...
Breaking Medicine News(10 mins):
(Date:11/26/2015)... , November 26, 2015 ... "Self Administration of High Viscosity Drugs" ... ) has announced the addition of the ... to their offering. --> Research and ... of the "Self Administration of High Viscosity ...
(Date:11/25/2015)... total global healthcare industry is expected to grow at a ... has the highest projected growth at 12.7%, and ... ), is second with growth projected at 11.5%. ... In 2013-2014, total government funded healthcare was nearly 68%. Federal ... in 2013-2014. In real terms, out of pocket expenditure increased ...
(Date:11/25/2015)... -- On Tuesday, November 24, 2015, the jury ... Medical Technology, Inc. for product liability and misrepresentation ... device, awarded $11 million in favor of Plaintiff ... three days of deliberations, the jury found that ... and unreasonably dangerous, and that Wright Medical made ...
Breaking Medicine Technology: